Monthly Olanzapine Injection Approved; Weight Gain Noted
Adults with schizophrenia gain a once-monthly option, though weight gain was the most common long-term side effect in trial participants.
Updated on Nov. 3, 2026 in Weight Loss

The FDA approved once-monthly subcutaneous olanzapine, branded Weltruza, for adults with schizophrenia on October 9, 2026. Long-term data from the phase 3 SOLARIS trial show weight gain was the most common side effect, a finding relevant to adults managing both mental health and weight.
Why it matters
Olanzapine is an antipsychotic whose metabolic side effects, including weight gain, are a well-known concern for people taking it long term. A monthly injectable formulation may change how often patients are dosed, while the weight data highlight a tradeoff clinicians and patients will need to weigh.
The SOLARIS phase 3 trial found all three subcutaneous olanzapine doses (318 mg, 425 mg, and 531 mg) improved PSP scale scores significantly more than placebo at week 8. In the long-term analysis, increased weight was the most common treatment-emergent adverse event, reported by 36% of participants.
The players
Teva
Teva is a pharmaceutical company whose portfolio includes long-acting injectable treatments for psychiatric conditions, and it released long-term SOLARIS safety data in September 2025.
Christoph Correll, MD
Correll is a clinical professor of psychiatry at the Zucker School of Medicine at Hofstra/Northwell who served as coordinating investigator for the phase 3 SOLARIS trial.
U.S. Food and Drug Administration
The FDA is the federal agency responsible for reviewing and approving prescription drugs in the United States, including the approval of this olanzapine formulation.
The details
The new formulation reaches blood levels within one to two days without oral cotreatment, a loading dose, a booster injection, or post-injection observation. Because it avoids daily pills, it offers a different delivery pattern from oral olanzapine. Weight gain remains a known metabolic effect of the drug class, and the trial data place it at the center of the long-term safety picture.
Timeline
October 9, 2026: FDA approves once-monthly subcutaneous olanzapine (Weltruza) for adults with schizophrenia.
November 3, 2026: HCPLive publishes an interview with trial investigator Christoph Correll, MD.
Health Landscape
Long-acting injectable antipsychotics have been used to address adherence challenges in schizophrenia care, where missed oral doses can contribute to relapse. This approval adds a monthly subcutaneous option to that treatment landscape, with its metabolic profile now a central point of evaluation.
If you or a family member take an antipsychotic, weight changes are worth tracking and raising at your next appointment. Any question about switching to a different formulation or medication is one to discuss with the prescribing clinician rather than decide alone.
The takeaway
The long-term data show weight gain was the most common side effect of this new olanzapine formulation, so tracking weight is a practical step for patients. Ask your prescriber how metabolic side effects will be monitored before any treatment change.
Further reading
Explore more on Weight Loss to see how medication-related weight gain fits into broader weight management.
Source note: This article includes information reported by Hcplive.





